Collaborations & Partnerships in the Pharma & Biotech Industries

Venue: The Hatton

Location: London, United Kingdom

Event Date/Time: Jun 30, 2003 End Date/Time: Jul 01, 2003
Report as Spam

Description

Discover the latest developments in...
Collaborations & Partnerships in the Pharma & Biotech Industries
30th June & 1st July 2003, The Hatton, London

A unique opportunity to learn from leading industry experts including:
Dr Ian Kirk, Discovery Alliances Manager, AstraZeneca
Dr William Harrison, Head, Global Search & Evaluation Europe, Business Development & Licensing, Novartis
Prof Ray Hill, Executive Director, Licensing & External Research, Europe, Merck
Dr Peter Johann, Head, Corporate Division, Corporate Development, Boehringer Ingelheim
Dr Wolfgang Schmidt, Scientific Affairs, Aventis
Dr Stefan Fischer, Global Alliance Director, Hoffman-La Roche
Joshua Kalkstein, Assistant General Counsel, Pfizer
Rimma Sandler Bradley, Worldwide Alliances, Licensing & Acquisitions, Procter & Gamble
Mehernosh Lentin, European Supply Chain Director, Baxter
Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics
Dr Bart Wuurman, Director, Business Development, Antisoma

Benefits of attending:
COLLABORATIONS: explore the opportunities that arise from working together with other pharma or biotech companies
PARTNERSHIPS: find out how to create lasting relationships
EFFECTIVE DEAL-MAKING: learn about the benefits derived from due diligence
LICENSING: discover the key success factors in optimising a drugs commercial potential
MERGERS AND ACQUISITIONS: find out how M & A can accelerate corporate development
THE MARKET, THE COMPETITION: comparing collaborations in Europe and America

Also:
INTERACTIVE DISCUSSION – Managing Partnerships: an opportunity to discuss the key issues with industry experts on the panel
Day One – 30th June 2003

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks
Michael Stone, Of Counsel, Covington & Burling

MANAGING PARTNERSHIPS
9.10 Creating lasting relationships
 Choosing the right partner
 Building support for both parties
 Managing conflicts
 Continuous improvement
 Reaching and measuring goals
Dr Ian Kirk, Discovery Alliances Manager, AstraZeneca

SETTING EXPECTATIONS
9.40 Thinking both sides of a deal
 The importance of understanding each sides needs
 Helping your partner to see your view
 Hard and soft aspects of negotiation
 Explanatory vs exploratory tactics
Dr Jim Phillips, Managing Director, Diabetology

MANAGING ALLIANCE CAPABILITY AND SUCCESS
10.20 Alliances
 Alliances beyond contracts
 Building alliance management capabilities
 Alignment between the two companies
Rimma Sandler Bradley, Worldwide Alliances, Licensing & Acquisitions, Procter & Gamble

11.00 Morning Coffee

NOVARTIS GLOBAL SEARCH & EVALUATION
11.20 A three year retrospective
Dr William Harrison, Head, Global Search & Evaluation Europe, Business Development & Licensing, Novartis

BIOLOGICAL ADVANCES
12.00 Changing the role of biotech and big pharma
 Where are the key biological discoveries being made?
 How does big pharma ensure access to the best drug discovery targets?
 Can biotech exploit its discoveries without the aid of big pharma?
 Exploiting synergies between large and small companies to the benefit of both
Prof Ray Hill, Executive Director, Licensing & External Research, Europe, Merck

12.40 Networking Lunch

LESSONS LEARNT FROM BIOTECH AND BIOTECH COLLABORATIONS
1.40 Advantages over pharma
 Structural aspects of pharma and biotech
 Comparing collaborations in Europe and America
 The market, the competition
 What does the future hold for big pharma?
Dr Stefan Fischer, Global Alliance Director, Hoffman-La Roche

PARTNERING WITH PHARMA
2.20 A financial and strategic necessity for Galapagos
 Rational for partnerships in a hybrid biotech business model
 Advantages of partnerships for directing the strategic research choices
 Impact of partnerships on the biotech cashflow and the confidence of its investors
 The SilenceSelect partnership offering as case study
Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics

ENTREPRENEURSHIP AND ALLIANCES IN LIFE SCIENCE AND CHEMISTRY
3.00 Overview of activities within Aventis to support and develop entrepreneurship in Life Sciences and Chemistry
 Complementary activities including specified business plan, competition projects and venture capital programs, create foundation of innovative SMEs in this area
 Support in marketing and management activities to ensure sustainable development of these companies
 Innovative SMEs are valuable partners in alliances with Aventis
 Several corporations describe the value of this strategy
Dr Wolfgang Schmidt, Scientific Affairs, Aventis

3.40 Afternoon Tea

THE ROCHE – ANTISOMA ALLIANCE
4.00 An alternative to acquisition or straight licensing
 Goals of the collaboration
 Collaboration structure
 Strategic implications
 Practical implications for Antisoma
Dr Bart Wuurman, Director, Business Development, Antisoma

PANEL DISCUSSION

MANAGING PARTNERSHIPS
4.40 Creating lasting relationships
Chair: Michael Stone, Of Counsel, Covington & Burling
Dr Ian Kirk, Discovery Alliances Manager, AstraZeneca
Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics
Prof Ray Hill, Executive Director, Licensing & External Research, Europe, Merck
Rod Richards, Chief Executive Officer, Microscience

5.20 Chairman’s Closing Remarks and Close of Day One

Day Two - 1st July 2003

8.30 Re-registration & Coffee

9.00 Chairman's Opening Remarks
Dr Paul Haycock, Director, Apax Partners

COLLABORATIONS IN COMBINATION THERAPIES
9.10 Unique aspects of collaboration in combination therapies
 Working with competing partners
 Timing of collaborations and marketing agreements
 Late stage opportunities
 In-licensing of technologies vs corporate acquisition
 Risks/rewards associated with acquisition vs in-licensing
Larry Stambaugh, Chairman, President & Chief Executive Officer, Maxim Pharmaceuticals

BUILDING A SUCCESSFUL BIOTECH COMPANY
9.40 Riding the financing rollercoaster
 Management, management, management
 Seed to start-up
 The £1-5m gap
 Serious VC financing
 Where is everyone’s exit?
Dr Paul Haycock, Director, Apax Partners

MORE EFFECTIVE DEAL MAKING
10.20 Benefits derived from due diligence
 Drivers from collaboration and types of deals
 Why many consolidating deals fail to deliver the promised value
 How to improve the probability that deals will deliver
 The importance of rigorous and independent due diligence
 Best practice in due diligence
 The importance of following through with full implementation
Dr Nigel Whittle, Principal Consultant, PA Consulting

11.00 Morning Coffee

INTELLECTUAL PROPERTY ISSUES IN PARTNERING
11.20 Key issues for consideration
 Intellectual property due diligence
 Key intellectual property issues in negotiating partnerships
 Case law considerations
 Strategies to maximise protection
Dr David Harper, Partner, McDonnell, Boehnen, Hulbert & Berghoff

MANAGING MULTIPLE PARTNERSHIPS
12.00 Importance of partnerships
 Partnering is an essential element of future growth
 Licensors intend to keep development and marketing rights requiring collaboration structures
 Dedicated structures to address complexity
 Experience with governance structures
Dr Peter Johann, Head, Corporate Division, Corporate Development, Boehringer Ingelheim

12.40 Networking Lunch

PATENT LAW RESEARCH EXEMPTION
1.40 Access to research tools in the 21st century biomedical research
 State of the law in the UK and Japan
 Hatch-Waxman Act and Roche vs Bolar
 Madey vs Duke
 Bristol-Myers Squibb vs Rhone Poulenc
 Bayh-Dole Act and 1999 NIH Guidelines
 The way to the future?
Joshua Kalkstein, Assistant General Counsel, Pfizer

USING M & A AS A MEANS TO ACCELERATE CORPORATE DEVELOPMENT
2.20 Selective use of M & A can provide a complementary approach to in-licensing both for R & D programmes and commercial products
 Goals for M & A activity
 Transformation of the business model
 Expanding geographic footprint
 Augmenting technology platforms
 Augmenting product pipeline
 Strategic considerations
 M & A in tandem with licensing and partnership models
Ian Nicholson, Director, Business Development, Celltech Group

COMPETITIVE INTELLIGENCE
3.00 How competitive intelligence creates opportunities in the pharmaceutical and biotech industries
 What competitive intelligence is and what it is not!
 Competitive intelligence in the pharmaceutical industry
 Why is it used?
 When is it used?
 How is it used?
 Competitive intelligence used specifically in collaborations and partnerships
Richard Withers, Managing Director, Europe, Fuld & Co.

3.40 Afternoon Tea

INTEGRATED LICENSING
4.00 Optimising a drugs commercial potential
 Definition of ‘integrated licensing’
 What are a development company’s strategic considerations for the commercial optimisation of its pipeline?
 How can integrated licensing company help a development company realise the full commercial potential of its pipeline portfolio?
 Case studies demonstrating the successful development of ‘unselected’ drug candidates
 Key success factors for win-win partnerships with integrated licensing companies
Kevin Quinn, Manager, Business Planning & Information, Helsinn Healthcare

MANAGING CONTINGENCY PLANNING WITH ARMED SERVICES
4.40 How industry collaboration can bring efficiencies into planning and procurement process
 Current process of procurement and disposal is expensive
 Expensive and lack of reactivity is the end result
 How to develop an operating model
 Funding the process model
 Setting the deal
 Establishing the on-going relationship
Mehernosh Lentin, European Supply Chain Director, Baxter

5.20 Chairman's Closing Remarks and Close of Conference










“Given the list of confirmed speakers and the topics, I am convinced that this event is going to be successful and fruitful for all participants”
Dr Roland Mohr, Head, Site Operations, Aventis

Discover the latest developments in...
Collaborations & Partnerships in the Pharma & Biotech Industries
30th June & 1st July 2003, The Hatton, London

A unique opportunity to learn from leading industry experts including:
Dr Ian Kirk, Discovery Alliances Manager, AstraZeneca
Dr William Harrison, Head, Global Search & Evaluation Europe, Business Development & Licensing, Novartis
Prof Ray Hill, Executive Director, Licensing & External Research, Europe, Merck
Dr Peter Johann, Head, Corporate Division, Corporate Development, Boehringer Ingelheim
Dr Wolfgang Schmidt, Scientific Affairs, Aventis
Dr Stefan Fischer, Global Alliance Director, Hoffman-La Roche
Joshua Kalkstein, Assistant General Counsel, Pfizer
Rimma Sandler Bradley, Worldwide Alliances, Licensing & Acquisitions, Procter & Gamble
Mehernosh Lentin, European Supply Chain Director, Baxter
Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics
Dr Bart Wuurman, Director, Business Development, Antisoma

Benefits of attending:
COLLABORATIONS: explore the opportunities that arise from working together with other pharma or biotech companies
PARTNERSHIPS: find out how to create lasting relationships
EFFECTIVE DEAL-MAKING: learn about the benefits derived from due diligence
LICENSING: discover the key success factors in optimising a drugs commercial potential
MERGERS AND ACQUISITIONS: find out how M & A can accelerate corporate development
THE MARKET, THE COMPETITION: comparing collaborations in Europe and America

Also:
INTERACTIVE DISCUSSION – Managing Partnerships: an opportunity to discuss the key issues with industry experts on the panel
Day One – 30th June 2003

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks
Michael Stone, Of Counsel, Covington & Burling

MANAGING PARTNERSHIPS
9.10 Creating lasting relationships
 Choosing the right partner
 Building support for both parties
 Managing conflicts
 Continuous improvement
 Reaching and measuring goals
Dr Ian Kirk, Discovery Alliances Manager, AstraZeneca

SETTING EXPECTATIONS
9.40 Thinking both sides of a deal
 The importance of understanding each sides needs
 Helping your partner to see your view
 Hard and soft aspects of negotiation
 Explanatory vs exploratory tactics
Dr Jim Phillips, Managing Director, Diabetology

MANAGING ALLIANCE CAPABILITY AND SUCCESS
10.20 Alliances
 Alliances beyond contracts
 Building alliance management capabilities
 Alignment between the two companies
Rimma Sandler Bradley, Worldwide Alliances, Licensing & Acquisitions, Procter & Gamble

11.00 Morning Coffee

NOVARTIS GLOBAL SEARCH & EVALUATION
11.20 A three year retrospective
Dr William Harrison, Head, Global Search & Evaluation Europe, Business Development & Licensing, Novartis

BIOLOGICAL ADVANCES
12.00 Changing the role of biotech and big pharma
 Where are the key biological discoveries being made?
 How does big pharma ensure access to the best drug discovery targets?
 Can biotech exploit its discoveries without the aid of big pharma?
 Exploiting synergies between large and small companies to the benefit of both
Prof Ray Hill, Executive Director, Licensing & External Research, Europe, Merck

12.40 Networking Lunch

LESSONS LEARNT FROM BIOTECH AND BIOTECH COLLABORATIONS
1.40 Advantages over pharma
 Structural aspects of pharma and biotech
 Comparing collaborations in Europe and America
 The market, the competition
 What does the future hold for big pharma?
Dr Stefan Fischer, Global Alliance Director, Hoffman-La Roche

PARTNERING WITH PHARMA
2.20 A financial and strategic necessity for Galapagos
 Rational for partnerships in a hybrid biotech business model
 Advantages of partnerships for directing the strategic research choices
 Impact of partnerships on the biotech cashflow and the confidence of its investors
 The SilenceSelect partnership offering as case study
Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics

ENTREPRENEURSHIP AND ALLIANCES IN LIFE SCIENCE AND CHEMISTRY
3.00 Overview of activities within Aventis to support and develop entrepreneurship in Life Sciences and Chemistry
 Complementary activities including specified business plan, competition projects and venture capital programs, create foundation of innovative SMEs in this area
 Support in marketing and management activities to ensure sustainable development of these companies
 Innovative SMEs are valuable partners in alliances with Aventis
 Several corporations describe the value of this strategy
Dr Wolfgang Schmidt, Scientific Affairs, Aventis

3.40 Afternoon Tea

THE ROCHE – ANTISOMA ALLIANCE
4.00 An alternative to acquisition or straight licensing
 Goals of the collaboration
 Collaboration structure
 Strategic implications
 Practical implications for Antisoma
Dr Bart Wuurman, Director, Business Development, Antisoma

PANEL DISCUSSION

MANAGING PARTNERSHIPS
4.40 Creating lasting relationships
Chair: Michael Stone, Of Counsel, Covington & Burling
Dr Ian Kirk, Discovery Alliances Manager, AstraZeneca
Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics
Prof Ray Hill, Executive Director, Licensing & External Research, Europe, Merck
Rod Richards, Chief Executive Officer, Microscience

5.20 Chairman’s Closing Remarks and Close of Day One

Day Two - 1st July 2003

8.30 Re-registration & Coffee

9.00 Chairman's Opening Remarks
Dr Paul Haycock, Director, Apax Partners

COLLABORATIONS IN COMBINATION THERAPIES
9.10 Unique aspects of collaboration in combination therapies
 Working with competing partners
 Timing of collaborations and marketing agreements
 Late stage opportunities
 In-licensing of technologies vs corporate acquisition
 Risks/rewards associated with acquisition vs in-licensing
Larry Stambaugh, Chairman, President & Chief Executive Officer, Maxim Pharmaceuticals

BUILDING A SUCCESSFUL BIOTECH COMPANY
9.40 Riding the financing rollercoaster
 Management, management, management
 Seed to start-up
 The £1-5m gap
 Serious VC financing
 Where is everyone’s exit?
Dr Paul Haycock, Director, Apax Partners

MORE EFFECTIVE DEAL MAKING
10.20 Benefits derived from due diligence
 Drivers from collaboration and types of deals
 Why many consolidating deals fail to deliver the promised value
 How to improve the probability that deals will deliver
 The importance of rigorous and independent due diligence
 Best practice in due diligence
 The importance of following through with full implementation
Dr Nigel Whittle, Principal Consultant, PA Consulting

11.00 Morning Coffee

INTELLECTUAL PROPERTY ISSUES IN PARTNERING
11.20 Key issues for consideration
 Intellectual property due diligence
 Key intellectual property issues in negotiating partnerships
 Case law considerations
 Strategies to maximise protection
Dr David Harper, Partner, McDonnell, Boehnen, Hulbert & Berghoff

MANAGING MULTIPLE PARTNERSHIPS
12.00 Importance of partnerships
 Partnering is an essential element of future growth
 Licensors intend to keep development and marketing rights requiring collaboration structures
 Dedicated structures to address complexity
 Experience with governance structures
Dr Peter Johann, Head, Corporate Division, Corporate Development, Boehringer Ingelheim

12.40 Networking Lunch

PATENT LAW RESEARCH EXEMPTION
1.40 Access to research tools in the 21st century biomedical research
 State of the law in the UK and Japan
 Hatch-Waxman Act and Roche vs Bolar
 Madey vs Duke
 Bristol-Myers Squibb vs Rhone Poulenc
 Bayh-Dole Act and 1999 NIH Guidelines
 The way to the future?
Joshua Kalkstein, Assistant General Counsel, Pfizer

USING M & A AS A MEANS TO ACCELERATE CORPORATE DEVELOPMENT
2.20 Selective use of M & A can provide a complementary approach to in-licensing both for R & D programmes and commercial products
 Goals for M & A activity
 Transformation of the business model
 Expanding geographic footprint
 Augmenting technology platforms
 Augmenting product pipeline
 Strategic considerations
 M & A in tandem with licensing and partnership models
Ian Nicholson, Director, Business Development, Celltech Group

COMPETITIVE INTELLIGENCE
3.00 How competitive intelligence creates opportunities in the pharmaceutical and biotech industries
 What competitive intelligence is and what it is not!
 Competitive intelligence in the pharmaceutical industry
 Why is it used?
 When is it used?
 How is it used?
 Competitive intelligence used specifically in collaborations and partnerships
Richard Withers, Managing Director, Europe, Fuld & Co.

3.40 Afternoon Tea

INTEGRATED LICENSING
4.00 Optimising a drugs commercial potential
 Definition of ‘integrated licensing’
 What are a development company’s strategic considerations for the commercial optimisation of its pipeline?
 How can integrated licensing company help a development company realise the full commercial potential of its pipeline portfolio?
 Case studies demonstrating the successful development of ‘unselected’ drug candidates
 Key success factors for win-win partnerships with integrated licensing companies
Kevin Quinn, Manager, Business Planning & Information, Helsinn Healthcare

MANAGING CONTINGENCY PLANNING WITH ARMED SERVICES
4.40 How industry collaboration can bring efficiencies into planning and procurement process
 Current process of procurement and disposal is expensive
 Expensive and lack of reactivity is the end result
 How to develop an operating model
 Funding the process model
 Setting the deal
 Establishing the on-going relationship
Mehernosh Lentin, European Supply Chain Director, Baxter

5.20 Chairman's Closing Remarks and Close of Conference

Venue

The Hatton
51-53 Hatton Gardens
London
United Kingdom
MORE INFO ON THIS VENUE

Additional Information

For registration please contact Mali Cook on 0044 20 7827 6142 or email mcook@smi-online.co.uk.